glp 1 medicaid The case for maintaining coverage for GLP-1s to treat obesity in Rhode Island • Rhode Island Current Biden administration plans to expand

Explore the study delving into GLP-1 RA medications adherence among diabetes patients

Haverly is an expert LASIK and Cataract surgeon

An obesity medicine specialist explains why thats not a good idea.

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

A major new study reveals that women who discontinued these medications gained over 3 kg more during pregnancy compared to those who never used them